Krishna Institute of Medical Sciences (NSE:KIMS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Krishna Institute of Medical Sciences EBITDA Margin % Related Terms
Krishna Institute of Medical Sciences EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krishna Institute of Medical Sciences EBITDA Margin % Chart
NSE:KIMS vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Krishna Institute of Medical Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krishna Institute of Medical Sciences EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Krishna Institute of Medical Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Krishna Institute of Medical Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krishna Institute of Medical Sciences (NSE:KIMS) has a EBITDA Margin % of 19.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krishna Institute of Medical Sciences and its competitors. This is 28% below median its historical median of 26.79. Over the past decade, Krishna Institute of Medical Sciences' EBITDA Margin % has ranged from 9.34 to 33.05. According to the industry distribution chart, Krishna Institute of Medical Sciences ranks #153 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 22.9%.
Is Krishna Institute of Medical Sciences' EBITDA Margin % too high?
Krishna Institute of Medical Sciences' current EBITDA Margin % of 19.35% is 28% below median its 10-year median of 26.79. Over the past 10 years, this metric has ranged from a low of 9.34 to a high of 33.05. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Krishna Institute of Medical Sciences' value of 19.35% is 89.5% above this industry median. Based on the distribution chart, Krishna Institute of Medical Sciences ranks #153 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Krishna Institute of Medical Sciences has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krishna Institute of Medical Sciences' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Krishna Institute of Medical Sciences ranks #153 out of 668 companies for EBITDA Margin %. This places Krishna Institute of Medical Sciences in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Krishna Institute of Medical Sciences' value of 19.35% is 89.5% above this benchmark. Historically, Krishna Institute of Medical Sciences' own EBITDA Margin % has ranged from 9.34 to 33.05 over the past decade. While the company's 10-year median is 26.79 vs. the industry median of 10.21, Krishna Institute of Medical Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krishna Institute of Medical Sciences's current EBITDA Margin % of 19.35% is 89.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krishna Institute of Medical Sciences and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krishna Institute of Medical Sciences's current EBITDA Margin % is 19.35%, which is 28% below median its own 10-year median of 26.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krishna Institute of Medical Sciences stock overvalued right now?
Based on GuruFocus' analysis, Krishna Institute of Medical Sciences (NSE:KIMS) is currently considered Fairly Valued. The stock's GF Value™ is ₹776.44, compared to a current price of ₹795.35 — trading 2.4% above its estimated fair value. The current EBITDA Margin % is 19.35%, which is 28% below median its 10-year median of 26.79 and 89.5% above the Healthcare Providers & Services industry median of 10.21. Krishna Institute of Medical Sciences' overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Krishna Institute of Medical Sciences (NSE:KIMS), the current EBITDA Margin % is 19.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krishna Institute of Medical Sciences (NSE:KIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Krishna Institute of Medical Sciences stock appears to be overvalued.
The current stock price of ₹795.35 is trading 2.4% above its estimated GF Value™ of ₹776.44.
GuruFocus considers Krishna Institute of Medical Sciences to be Fairly Valued.
Key valuation signals for NSE:KIMS:
EBITDA Margin %: 19.35% (28% below median its 10-year median of 26.79)
GF Value™: ₹776.44 vs. price of ₹795.35 (2.4% above fair value)
Industry Position: 89.5% above the Healthcare Providers & Services median (#153 of 668)
No single metric tells the full story. See the NSE:KIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krishna Institute of Medical Sciences Business Description
Krishna Institute of Medical Sciences Ltd is a healthcare group in Secunderabad and Telangana. It offers a comprehensive range of healthcare services, including oncology, cardiac sciences, neurosciences, gastric sciences, orthopedics, renal sciences, organ transplantation, mother and child care, and many more. The firm generates key revenue from Hospital services and Pharmacy.
87GF Score
Get the complete analysis for NSE:KIMS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KIMS has been successfully added to your 
